Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock Price Up 4.9% – Here’s What Happened

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) shares shot up 4.9% on Monday. The company traded as high as $22.1350 and last traded at $22.1350. 115 shares were traded during trading, a decline of 93% from the average session volume of 1,668 shares. The stock had previously closed at $21.10.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Barclays upgraded Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Hikma Pharmaceuticals Price Performance

The stock has a 50-day simple moving average of $21.75 and a 200-day simple moving average of $20.35.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad range of generic, branded and specialty medicines. Its portfolio includes injectable medicines, oral solid-dose products, inhalation products and other treatments used in hospitals, pharmacies and community-care settings.

The company operates through three principal businesses: Injectables, Generics and Branded Medicines. Hikma supplies injectable products to hospitals and healthcare providers, offers generic medicines primarily in the United States, and markets branded and licensed medicines across the Middle East and North Africa.